Category: CRG actions

Consultation: actions from September 2023 CRG meeting

September 15, 2023

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their September 2023 meeting. Actions in this consultation include:

  • Tadalafil 5mg once daily – remove from DNP list and assign GREEN RAG status
  • Herbal treatments – DNP listing amended to “herbal treatments and other natural products”, in line with NHS England guidance
  • Cipaglucosidase alfa – add to formulary as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 27th October 2023. To take part, visit the consultations page.

Consultation: actions from August 2023 CRG meeting

August 11, 2023

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their August 2023 meeting. Actions in this consultation include:

  • Sodium chloride 5% eye drops – RED
  • Bempedoic acid – comments sought regarding a change to GREEN
  • Steroid eye drops (betamethasone 0.1%, dexamethasone 0.1%, prednisolone 0.03%, 0.1%, 0.5% & 1%, fluorometholone 0.1%) – GREEN (specialist initiation)
  • Rimegepant for preventing migraine – GREEN (specialist initiation) OR GREEN (specialist advice)
  • Semaglutide for overweight and obesity in young people aged 12-17 years – Do Not Prescribe.

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 22nd September 2023. To take part, visit the consultations page.

Consultation: actions from July CRG meeting

July 18, 2023

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their July 2023 meeting. Actions in this consultation include:

  • Bulevirtide for chronic hepatitis D – add to formulary as RED
  • Esketamine for major depressive disorder in adults at imminent risk of suicide – update existing DNP listing to include this indication
  • Dapagliflozin for chronic heart failure with preserved or mildly reduced ejection fraction – add to formulary as GREEN (following specialist advice)
  • Upadacitinib for Crohn’s disease – add to formulary as RED
  • Deucravactinib for plaque psoriasis – add to formulary as RED
  • Emollient bath additives – update DNP listing to include reference to new NICE ‘do not do’ recommendation

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Tuesday 29th August 2023. To take part, visit the consultations page.

Consultation: actions from June CRG meeting

June 16, 2023

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their June 2023 meeting. Actions in this consultation include:

  • Hydrocortisone 0.5% ointment, and 2.5% cream and ointment – add to Do Not Prescribe list
  • Infliximab 120mg pre-filled syringe / pen and vedolizumab 108mg pre-filled syringe / pen – RED
  • Risankizumab for moderately to severely active Crohn’s disease – RED
  • Voclosporin with mycophenolate for lupus nephritis – RED
  • Difelikefalin for pruritus in haemodialysis – RED
  • Tranexamic acid injection – RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Friday 28th July 2023.

Consultation: actions from May CRG meeting

May 12, 2023

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their May 2023 meeting. Actions in this consultation include:

  • Fosfomycin 3g oral sachets for uncomplicated UTI in non-pregnant women – to be GREEN
  • Tezepelumab for severe asthma – to be RED

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Friday 23rd June 2023.

Consultation: actions from January 2023 meeting of CRG

January 23, 2023

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the January 2023 CRG meeting.

Actions in this consultation include:

  • Avatrombopag added to formulary as a RED drug for primary chronic immune thrombocytopenia.
  • Esketamine nasal spray for treatment-resistant depression added to the DNP list.

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Monday 6th March 2023.

Consultation: actions from December meeting of CRG

December 15, 2022

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the December 2022 CRG meeting.

Actions in this consultation include:

  • Donepezil, galantamine and rivastigmine for mild to moderate Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease: Green (specialist advice)
  • Cyclogest added to formulary as an option for vaginal micronised progesterone for prevention of miscarriage

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Thursday 26th January 2023.

Consultation: actions from November meeting of CRG

November 11, 2022

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the November 2022 CRG meeting.

Actions in this consultation include:

  • Ozanimod for moderately to severely active ulcerative colitis – RED
  • Relugolix / estradiol / norethisterone for moderate to severe symptoms of uterine fibroids – GREEN (following specialist advice)
  • Remove fostamatinib from DNP list and assign a RED status
  • Replace links to superseded NICE clinical guideline CG177 with links to NG226: Osteroarthritis in over 16s. Formulary note regarding glucosamine updated to read “Do not offer glucosamine products or strong opioids for the management of osteoarthritis.”

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Friday 23rd December 2022.

Consultation: actions from October meeting of CRG

October 17, 2022

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the October 2022 CRG meeting.

Actions in this consultation include:

  • Estradiol and testosterone for gender dysphoria (when under NHS care) – GREEN (following specialist initiation)
  • Dexcom One real-time CGM system – to be available as an alternative first-line option to FreeStyle Libre.
  • Chloral hydrate & chloral betaine – RED
  • Dexamethasone intravitreal implant for diabetic macular oedema – update links to reflect latest NICE technology appraisal
  • Avacopan for severe active granulomatosis with polyangitis or microscopic polyangitis – added to RAG list only as RED
  • Upadacitinib for active ankylosing spondylitis – RED

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Monday 28th November 2022.

Consultation: actions from July meeting of CRG

July 25, 2022

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the July 2022 CRG meeting.

Actions in this consultation include:

  • Ranibizumab biosimilar to be added to formulary as RED, and ranibizumab to be first choice anti-VEGF therapy for NICE-approved indications.
  • Melatonin (Adaflex) to be added to formulary as AMBER (children) and GREEN (specialist advice) for adults with REM sleep behaviour disorder in Parkinson’s disease.
  • Mexiletine – RED for life-threatening ventricular arrhythmias
  • Filgotinib – RED for moderately to severely active ulcerative colitis
  • Faricimab – RED for diabetic macular oedema and wet age-related macular degeneration
  • Diroximel fumarate – RED for relapsing-remitting multiple sclerosis
  • Teduglutide – RED for short bowel syndrome
  • NICE clinical guideline for gout, NG219, to add to formulary.

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Monday 5th September 2022.